Happel David 4
4 · Sagimet Biosciences Inc. · Filed Jul 23, 2025
Insider Transaction Report
Form 4
Happel David
DirectorPresident & CEO
Transactions
- Sale
Series A Common Stock
2025-07-21$9.13/sh−65,478$598,115→ 689,722 total
Footnotes (1)
- [F1]Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.